Correction to Oz, H.S.; Ebersole, Jeffrey L. Application of Prodrugs to Inflammatory Diseases of the Gut. Molecules 2008, 13, 452-474

We have been notified by Elsevier, the copyright holder, that the last paragraph on p. 457 of this review contained verbatim text from the abstract of the correctly attributed literature being discussed in that section the Molecules paper. The revised paragraph should read as follows:

Still in an exploratory stage, recently an amino acid (mutual) azo prodrug of 5-ASA was prepared for targeted drug delivery to the inflamed colonic tissue in IBD by coupling L-tryptophan with salicylic acid, [56]. The synthesized prodrug was found to be as effective as sulfasalazine in attenuating colitis in a TNBS-induced rat model without the ulceration side effects of 5-ASA.

The authors wish to apologize for this error, due to their use of the text subject to copyright as a placeholder in an earlier draft version of their review and its totally unintentional carryover into the final published version.